Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Steady State Magnetic Resonance Angiography of the Thoracic Aorta Using Inversion-recovery Steady-State Free Precession and a High Relaxivity Contrast Agent.

Abbasi MA, Serhal A, Reese O, Aouad P, Collins L, Blaisdell J, Collins J, Carr J.

J Thorac Imaging. 2020 Feb 19. doi: 10.1097/RTI.0000000000000487. [Epub ahead of print]

PMID:
32079906
2.

Donor and Recipient Characteristics in Heart Transplantation Are Associated with Altered Myocardial Tissue Structure and Cardiac Function.

Dolan RS, Rahsepar AA, Blaisdell J, Sarnari R, Ghafourian K, Wilcox JE, Khan SS, Vorovich EE, Rich JD, Yancy CW, Anderson AS, Carr JC, Markl M.

Radiol Cardiothorac Imaging. 2019 Dec 19;1(5):e190009. doi: 10.1148/ryct.2019190009.

PMID:
32076670
3.

Evaluating Biventricular Myocardial Velocity and Interventricular Dyssynchrony in Adult Patients During the First Year After Heart Transplantation.

Sarnari R, Blake AM, Ruh A, Abbasi MA, Pathrose A, Blaisdell J, Dolan RS, Ghafourian K, Wilcox JE, Khan SS, Vorovich EE, Rich JD, Anderson AS, Yancy CW, Carr JC, Markl M.

J Magn Reson Imaging. 2020 Feb 15. doi: 10.1002/jmri.27091. [Epub ahead of print]

PMID:
32061045
4.

Semi-quantitative myocardial perfusion MRI in heart transplant recipients at rest: repeatability in healthy controls and assessment of cardiac allograft vasculopathy.

DeSa TB, Abbasi MA, Blaisdell JA, Lin K, Collins JD, Carr JC, Markl M.

Clin Imaging. 2019 Dec 19;61:62-68. doi: 10.1016/j.clinimag.2019.12.011. [Epub ahead of print]

PMID:
31981959
5.

Natural History of Myocardial Late Gadolinium Enhancement Predicts Adverse Clinical Events in Heart Transplant Recipients.

Chaikriangkrai K, Abbasi MA, Sarnari R, Lee D, Anderson AS, Ghafourian K, Khan SS, Vorovich EE, Rich JD, Wilcox JE, Blaisdell JA, Yancy CW, Carr J, Markl M.

JACC Cardiovasc Imaging. 2019 Oct;12(10):2092-2094. doi: 10.1016/j.jcmg.2019.05.014. Epub 2019 Jul 17. No abstract available.

PMID:
31326473
6.

Prenatal exposure to nitrate in drinking water and the risk of congenital anomalies.

Blaisdell J, Turyk ME, Almberg KS, Jones RM, Stayner LT.

Environ Res. 2019 Sep;176:108553. doi: 10.1016/j.envres.2019.108553. Epub 2019 Jun 24.

PMID:
31325834
7.

Multiparametric Cardiac Magnetic Resonance Imaging Can Detect Acute Cardiac Allograft Rejection After Heart Transplantation.

Dolan RS, Rahsepar AA, Blaisdell J, Suwa K, Ghafourian K, Wilcox JE, Khan SS, Vorovich EE, Rich JD, Anderson AS, Yancy CW, Collins JD, Carr JC, Markl M.

JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 2):1632-1641. doi: 10.1016/j.jcmg.2019.01.026. Epub 2019 Mar 13.

PMID:
30878427
8.

Cardiac Structure-Function MRI in Patients After Heart Transplantation.

Dolan RS, Rahsepar AA, Blaisdell J, Lin K, Suwa K, Ghafourian K, Wilcox JE, Khan SS, Vorovich EE, Rich JD, Anderson AS, Yancy CW, Collins JD, Markl M, Carr JC.

J Magn Reson Imaging. 2019 Mar;49(3):678-687. doi: 10.1002/jmri.26275. Epub 2018 Aug 24.

PMID:
30142237
9.

Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis.

Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KL, Falk RJ.

Br J Clin Pharmacol. 2012 Sep;74(3):445-55. doi: 10.1111/j.1365-2125.2012.04223.x.

10.

CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.

Joy MS, Dornbrook-Lavender K, Blaisdell J, Hilliard T, Boyette T, Hu Y, Hogan SL, Candiani C, Falk RJ, Goldstein JA.

Eur J Clin Pharmacol. 2009 Sep;65(9):947-53. doi: 10.1007/s00228-009-0707-7. Epub 2009 Aug 11.

11.

Short and longer-term effects of creatine supplementation on exercise induced muscle damage.

Rosene J, Matthews T, Ryan C, Belmore K, Bergsten A, Blaisdell J, Gaylord J, Love R, Marrone M, Ward K, Wilson E.

J Sports Sci Med. 2009 Mar 1;8(1):89-96. eCollection 2009.

12.

A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.

Goldstein JA, Blaisdell JA, Limdi NA.

Blood Cells Mol Dis. 2009 Mar-Apr;42(2):155-8. doi: 10.1016/j.bcmd.2008.10.011. Epub 2008 Dec 11. No abstract available.

13.

Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.

Limdi N, Goldstein J, Blaisdell J, Beasley T, Rivers C, Acton R.

Per Med. 2007 May 1;4(2):157-169.

14.
15.

Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450.

Vyas PM, Roychowdhury S, Khan FD, Prisinzano TE, Lamba J, Schuetz EG, Blaisdell J, Goldstein JA, Munson KL, Hines RN, Svensson CK.

J Pharmacol Exp Ther. 2006 Oct;319(1):488-96. Epub 2006 Jul 20.

PMID:
16857728
16.

Oxidative DNA glycosylases: recipes from cloning to characterization.

Bandaru V, Blaisdell JO, Wallace SS.

Methods Enzymol. 2006;408:15-33.

PMID:
16793360
17.

Engineering functional changes in Escherichia coli endonuclease III based on phylogenetic and structural analyses.

Watanabe T, Blaisdell JO, Wallace SS, Bond JP.

J Biol Chem. 2005 Oct 7;280(40):34378-84. Epub 2005 Aug 11.

18.

Discovery of new potentially defective alleles of human CYP2C9.

Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA.

Pharmacogenetics. 2004 Aug;14(8):527-37.

PMID:
15284535
19.

Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities.

Wang H, Zhao Y, Bradbury JA, Graves JP, Foley J, Blaisdell JA, Goldstein JA, Zeldin DC.

Mol Pharmacol. 2004 May;65(5):1148-58.

PMID:
15102943
20.

Expression of the oxidative base excision repair enzymes is not induced in TK6 human lymphoblastoid cells after low doses of ionizing radiation.

Inoue M, Shen GP, Chaudhry MA, Galick H, Blaisdell JO, Wallace SS.

Radiat Res. 2004 Apr;161(4):409-17.

PMID:
15038771
21.

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.

Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA.

Pharmacotherapy. 2003 Jun;23(6):720-5.

PMID:
12820813
22.

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.

Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA.

Eur J Clin Pharmacol. 2003 Apr;58(12):791-4. Epub 2003 Feb 26.

PMID:
12698304
23.

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.

Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA.

J Clin Pharmacol. 2003 Jan;43(1):84-91.

PMID:
12520632
24.

Macular pucker removal with and without internal limiting membrane peeling: pilot study.

Park DW, Dugel PU, Garda J, Sipperley JO, Thach A, Sneed SR, Blaisdell J.

Ophthalmology. 2003 Jan;110(1):62-4.

PMID:
12511347
25.

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA.

Pharmacogenetics. 2002 Dec;12(9):703-11.

PMID:
12464799
26.

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.

Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA.

Clin Pharmacol Ther. 2002 Nov;72(5):562-71.

PMID:
12426520
27.

Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.

Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, Gaysornsiri D.

Pharmacogenetics. 2002 Apr;12(3):221-5.

PMID:
11927837
28.

Base excision repair processing of radiation-induced clustered DNA lesions.

Blaisdell JO, Harrison L, Wallace SS.

Radiat Prot Dosimetry. 2001;97(1):25-31. Review.

PMID:
11763354
29.

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA.

Pharmacogenetics. 2001 Dec;11(9):803-8.

PMID:
11740344
30.

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA.

Pharmacogenetics. 2001 Oct;11(7):597-607.

PMID:
11668219
31.

Abortive base-excision repair of radiation-induced clustered DNA lesions in Escherichia coli.

Blaisdell JO, Wallace SS.

Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7426-30. Epub 2001 Jun 12.

32.

Differential effects of inhaled nitric oxide and hyperoxia on pulmonary dysfunction in newborn guinea pigs.

Gries DM, Tam EK, Blaisdell JM, Iwamoto LM, Fujiwara N, Uyehara CF, Nakamura KT.

Am J Physiol Regul Integr Comp Physiol. 2000 Nov;279(5):R1525-30.

34.

A novel role for Escherichia coli endonuclease VIII in prevention of spontaneous G-->T transversions.

Blaisdell JO, Hatahet Z, Wallace SS.

J Bacteriol. 1999 Oct;181(20):6396-402.

35.

Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs.

Klose TS, Blaisdell JA, Goldstein JA.

J Biochem Mol Toxicol. 1999;13(6):289-95.

PMID:
10487415
36.

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA.

J Pharmacol Exp Ther. 1999 Aug;290(2):635-40.

PMID:
10411572
37.

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT.

Pharmacogenetics. 1999 Feb;9(1):71-80.

PMID:
10208645
38.

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.

Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA.

Pharmacogenetics. 1998 Apr;8(2):129-35.

PMID:
10022751
39.

Role of cardiac troponin I in the evaluation of myocardial injury.

Bhagavan NV, Goldstein AP, Honda SA, Uyehara J, Blaisdell J, Sugiyama C, Murakami L, Kang L, Fujitani G.

J Clin Lab Anal. 1998;12(5):276-9.

40.

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J.

J Pharmacol Exp Ther. 1998 Sep;286(3):1490-5.

PMID:
9732415
41.

Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid.

Luo G, Zeldin DC, Blaisdell JA, Hodgson E, Goldstein JA.

Arch Biochem Biophys. 1998 Sep 1;357(1):45-57.

PMID:
9721182
43.

Analysis of the mechanisms of action of the Saccharomyces cerevisiae dominant lethal cdc42G12V and dominant negative cdc42D118A mutations.

Davis CR, Richman TJ, Deliduka SB, Blaisdell JO, Collins CC, Johnson DI.

J Biol Chem. 1998 Jan 9;273(2):849-58.

44.

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA.

J Pharmacol Exp Ther. 1998 Jan;284(1):356-61.

PMID:
9435198
45.
46.

Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.

Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, Zhou HH.

J Pharmacol Exp Ther. 1997 Apr;281(1):604-9.

PMID:
9103550
47.

Effects of choreito and takushya consumption on in vitro and in vivo struvite solubility in cat urine.

Buffington CA, Blaisdell JL, Komatsu Y, Kawase K.

Am J Vet Res. 1997 Feb;58(2):150-2.

PMID:
9028479
48.

Effects of choreito consumption on urine variables of healthy cats fed a magnesium-supplemented commercial diet.

Buffington CA, Blaisdell JL, Kawase K, Komatsu Y.

Am J Vet Res. 1997 Feb;58(2):146-9.

PMID:
9028478
49.
50.

Clinical evaluation of cats with nonobstructive urinary tract diseases.

Buffington CA, Chew DJ, Kendall MS, Scrivani PV, Thompson SB, Blaisdell JL, Woodworth BE.

J Am Vet Med Assoc. 1997 Jan 1;210(1):46-50.

PMID:
8977647

Supplemental Content

Loading ...
Support Center